Evidence map›Paper›PMID 39861796›Full record

ArticleViruses2024

Effect of Fusion to the LTB Carrier Protein on Coronavirus Spike Protein Vaccine Candidates Produced in Maize.

Erin Egelkrout, Magdalena Maj, Rodrigo Manjarin, Gina Fake, Muneaki Watanabe, Jenna Williams, Nate Blanchard, John Walker, Celine Hayden, John Howard

Abstract read
In one paragraph

Article in Viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Erin EgelkroutApplied Biotechnology Institute, California Polytechnic Tech Park, San Luis Obispo, CA 93407, USA.
Magdalena MajDepartment of Biological Sciences, California Polytechnic State University, San Luis Obispo, CA 93407, USA.ORCID 0000-0003-3511-3788
Rodrigo ManjarinDepartment of Animal Sciences, California Polytechnic State University, San Luis Obispo, CA 93407, USA.ORCID 0000-0001-5691-1549
Gina FakeApplied Biotechnology Institute, California Polytechnic Tech Park, San Luis Obispo, CA 93407, USA.
Muneaki WatanabeApplied Biotechnology Institute, California Polytechnic Tech Park, San Luis Obispo, CA 93407, USA.ORCID 0009-0005-1963-7671
Jenna WilliamsDepartment of Biological Sciences, California Polytechnic State University, San Luis Obispo, CA 93407, USA.
Nate BlanchardDepartment of Biological Sciences, California Polytechnic State University, San Luis Obispo, CA 93407, USA.
John WalkerDepartment of Statistics, California Polytechnic State University, San Luis Obispo, CA 93407, USA.
Celine HaydenApplied Biotechnology Institute, California Polytechnic Tech Park, San Luis Obispo, CA 93407, USA.
John HowardApplied Biotechnology Institute, California Polytechnic Tech Park, San Luis Obispo, CA 93407, USA.

Funding

California State University System 58913
6 · The paper itself

Abstract

Coronaviruses continue to disrupt health and economic productivity worldwide. Porcine epidemic diarrhea virus (PEDV) is a devastating swine disease and SARS-CoV-2 is the latest coronavirus to infect the human population. Both viruses display a similar spike protein on the surface that is a target of vaccine development. Despite the availability of commercial vaccines for both viruses, there is still a high occurrence of infections and a great need for enhanced efficacy and lower costs. We previously produced the PEDV spike protein (S) using transgenic maize, enabling a low-cost supply of the vaccine candidate. In this study, we (1) test orally delivered PEDV vaccine candidates in pigs to optimize the mucosal immune response; (2) generate the SARS-CoV-2 S1 protein in maize; and (3) perform structural characterization of the S1 protein for PEDV and SARS-CoV-2. We demonstrated high expression levels in maize of the S1 subunit of the SARS-CoV-2 spike protein, both with and without fusion to the heat-labile enterotoxin B (LTB) subunit. We found that the LTB fusion protein from both coronaviruses preferentially assembles into higher molecular weight multimers, consistent with the formation of trimers. For PEDV, administering the spike protein fused to LTB to young pigs elicited a higher level of mucosal IgAs compared to maize grain containing the S1 protein alone or controls. This suggests that fusing the coronavirus spike protein with LTB may provide better protection.

Indexed as

COVID-19 VaccinesEnterotoxinsSpike Glycoprotein, CoronavirusViral VaccinesZea maysAnimalsAntibodies, ViralCOVID-19HumansImmunity, MucosalPlants, Genetically ModifiedPorcine epidemic diarrhea virusRecombinant Fusion ProteinsSARS-CoV-2SwineSwine DiseasesAntibodies, ViralCOVID-19 VaccinesEnterotoxinsRecombinant Fusion ProteinsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Viral Vaccinesmaizeoral deliveryPEDVplant-produced vaccinesSARS-CoV-2spike proteintrimer

Identifiers

PMID39861796
PMCPMC11768699

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.